Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients
Comparison of the Efficacy and Safety of Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt
- Tanta University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-70 years
- Cirrhotic patients complaining of frequent muscle cramps (>3 per week) for at least a month
Exclusion Criteria:
- Patients with allergy to study drugs
- Renal impairment
- Peripheral vascular disease
- Peripheral neuropathy
- Glaucoma
- Prostatic enlargement
- Pregnancy and lactation
- Patients taking calcium channel blockers, and conjugated estrogens
- Patients taking vitamin E, taurine, carnitine, narcotic pain medications, muscle relaxants, nonsteroidal anti-inflammatory drugs, or antispastic agents during and for 2 weeks following the study
- Patients with alcoholic cirrhosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: orphenadrine group
orphenadrine
|
100 mg twice daily
|
|
Active Comparator: Baclofen group
Baclofen
|
initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the difference in the number of muscle cramps between the orphenadrine and baclofen groups at the end of treatment
Time Frame: 12 weeks
|
Questionnaire
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The difference in severity of cramps between orphenadrine and baclofen groups at the end of treatment
Time Frame: 12 weeks
|
Visual analogue scale (VAS)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Assem Elfert, faculty of medicine, Tanta University
- Principal Investigator: Sherif Abd-Elsalam, faculty of medicine, Tanta University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Spasm
- Muscle Cramp
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Enzyme Inhibitors
- GABA Agents
- Cytochrome P-450 Enzyme Inhibitors
- Neuromuscular Agents
- Muscle Relaxants, Central
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Cytochrome P-450 CYP2B6 Inhibitors
- GABA Agonists
- GABA-B Receptor Agonists
- Orphenadrine
- Baclofen
Other Study ID Numbers
Other Study ID Numbers
- 2020-87
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.